Related Experiment Videos
Renal radiofrequency ablation: clinical status 2003
Paul F Zelkovic1, Martin I Resnick
1Department of Urology, University Hospitals of Cleveland/Case Western Reserve, Ohio, USA.
Current Opinion in Urology
|April 15, 2003
Summary
Radiofrequency ablation shows promise for treating small kidney tumors minimally invasively. Further research is needed to address technical issues before widespread clinical adoption for renal cell carcinoma.
Area of Science:
- Oncology
- Minimally Invasive Surgery
- Medical Technology
Background:
- Energy-based tumor ablation is emerging for renal cell carcinoma treatment.
- Radiofrequency ablation (RFA) is in phase II clinical trials for small renal tumors.
Purpose of the Study:
- To review the current status of clinical trials for radiofrequency ablation in treating small renal tumors.
- To evaluate the efficacy and limitations of RFA for renal cell carcinoma.
Main Methods:
- Review of phase II clinical trial data for radiofrequency ablation.
- Analysis of radiographic and pathologic outcomes in treated patients.
- Assessment of factors influencing RFA effectiveness (tumor size, location, energy delivery).
Main Results:
- Radiofrequency ablation demonstrated reproducible tumor destruction in animal models and clinical trials.
- Radiographic follow-up showed minimal to no residual contrast enhancement in most ablated small renal tumors.
- Pathologic evaluation revealed variability, with some tumors exhibiting residual viable tumor areas.
Conclusions:
- Radiofrequency ablation shows potential as a minimally invasive option for small renal tumors.
- Further technical advancements are required to optimize outcomes and establish RFA as a standard treatment.
- RFA remains an experimental therapy for renal cell carcinoma pending resolution of technical challenges.